# Evaluating the Response-Guided Therapy With Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer (JCOG2402, Young HOPE)

> **NCT07671885** · PHASE3 · RECRUITING · sponsor: **Tokyo Women's Medical University** · enrollment: 950 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Adjuvant systemic therapy based on pathological findings and ET response
- **DRUG:** Adjuvant systemic therapy based on pathological findings

## Key facts

- **NCT ID:** NCT07671885
- **Lead sponsor:** Tokyo Women's Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-28
- **Primary completion:** 2038-01-27
- **Final completion:** 2039-01-27
- **Target enrollment:** 950 (ESTIMATED)
- **Last updated:** 2026-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07671885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07671885, "Evaluating the Response-Guided Therapy With Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer (JCOG2402, Young HOPE)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07671885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*